Medical Letter On Drugs And Therapeutics

The Medical Letter, Inc. is committed to providing objective, practical, and timely information on drugs and treatments of common diseases to help our readers make the best decisions for their patients—without the influence of the pharmaceutical industry.

The Medical Letter On Drugs and Therapeutics is a biweekly publication that provides:

Evidence-based, peer-reviewed evaluations of new FDA-approved drugs with conclusions reached by a consensus of experts

New information on previously approved drugs including pivotal clinical trials, new indications, and safety warnings

Consensus recommendations for the preferred and alternative treatments for common disorders

Comparative reviews of drugs for a given indication with particular attention to clinical efficacy, adverse effects, drug interactions, and cost.

《医学快报》致力于提供客观、实用、及时的常见疾病药物和治疗信息，帮助我们的读者为患者做出最佳决策，不受制药行业的影响。

《医学快报：药物和治疗学》是一份双周刊，提供：

基于证据、同行评审的 FDA 批准新药评估，结论由专家达成共识

有关先前批准药物的新信息，包括关键临床试验、新适应症和安全警告

常见疾病首选和替代治疗的共识建议

针对特定适应症的药物进行比较性评价，特别关注临床疗效、不良反应、药物相互作用和成本。

该刊已被国际权威数据库SCIE收录，该刊致力于发表经过严格同行评审的高质量原创文章，反映医学-药学领域的新进展、新技术、新成果，促进该领域科研交流和科研成果转化。该刊2023年影响因子为1.4，平均审稿速度为 较慢,6-12周 ，近四年来没有被列入预警名单。如果您需要投稿发表服务及指导，可以联系我们的客服老师，我们专业专注服务期刊投稿协助10年，为您提供期刊投稿个性化定制服务，并且我们确保严格保密您的个人信息及稿件内容。